Amyloid cardiomyopathy in the elderly: clinical options, difficulties in diagnosis and treatment

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This article analyzes the frequency and features of cardiac amyloidosis in the elderly. The morphology and pathogenesis of amyloid cardiomyopathy are presented. The features of the clinical picture of the heart and aortic lesions in systemic and local variants of amyloidosis are analyzed. Polymorbidity in older people, which complicates the diagnosis of cardiac amyloidosis and leads to a delay in treatment, is reviewed. The diagnostic methods of various types of cardiac amyloidosis are evaluated. Modern trends in the treatment of amyloidosis are presented.

Full Text

Restricted Access

About the authors

Ol’ga A. Ettinger

N.I.Pirogov Russian National Research Medical University

Author for correspondence.
Email: exampl@mail.ru
ORCID iD: 0000-0002-1237-3731

MD, PhD

Russian Federation, 117997, Moscow

Gennadiy E. Gendlin

N.I.Pirogov Russian National Research Medical University

Email: exampl@mail.ru
ORCID iD: 0000-0002-7846-1611

MD, PhD, DSc, Professor

Russian Federation, 117997, Moscow

Elena A. Stepanova

V.M. Buyanov Moscow City Clinical Hospital; Russian Medical Academy of Continuing Professional Education

Email: exampl@mail.ru
ORCID iD: 0000-0001-7760-5858

врач-патологоанатом; ассистент кафедры патологической анатомии 

Russian Federation, 115056, Moscow; 125993, Moscow

Irina I. Ganieva

V.M. Buyanov Moscow City Clinical Hospital

Email: exampl@mail.ru
ORCID iD: 0000-0002-2429-1629

врач-кардиолог 

Russian Federation, 115056, Moscow

Svetlana V. Borisovskaya

N.I.Pirogov Russian National Research Medical University; V.M. Buyanov Moscow City Clinical Hospital

Email: exampl@mail.ru
ORCID iD: 0000-0002-9365-1472

MD, PhD

Russian Federation, 117997,Moscow; 115056, Moscow

Il’ya G. Fedorov

N.I.Pirogov Russian National Research Medical University; V.M. Buyanov Moscow City Clinical Hospital

Email: exampl@mail.ru

MD, PhD

Russian Federation, 117997, Moscow; 115056, Moscow

Igor’ G. Nikitin

N.I.Pirogov Russian National Research Medical University; Medical and Rehabilitation Center

Email: exampl@mail.ru
ORCID iD: 0000-0003-1699-0881

MD, PhD, DSc, Professor

Russian Federation, 125367, Moscow

References

  1. Benson M.D., Buxbaum J.N., Eisenberg D.S., Merlini G., Saraiva M.J.M., Sekijima Y., Sipe J.D., Westermark P. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018 Dec; 25(4): 215-9.
  2. Falk R., Comenzo R., Skinner M. The systemic amyloidoses N. Engl. J. Med. 1997: 337 (13): 898–909.
  3. Picken M.M., Dogan A., Herrera G.A., editors. Amyloid and Related Disorders Surgical Pathology and Clinical Correlations. 2-d edition. Heidelberg New York Dordrecht London: Humana Press, 2015. doi: 10.1007/978-3-319-19294-9.
  4. Bobrov A.L., Kulikov A.N., Gorokhova E.V., Rud’ S. D., Bobrov L.L. A case of fulminant development and progression of heart failure in heart amyloidosis. Rossiyskiy kardiologicheskiy zhurnal.2016; 2(130): 95–6. (in Russian)
  5. Demko I.V., Pelinovskaya L.I., Soloveva I.A., Kraposhina A.Yu., Gordeeva N.V., Mosina V.A. Primary cardiac amyloidosis. Klinicheskaya meditsina. 2017; 95(11): 971—6. (in Russian)
  6. Brenner D.A., Jain M., Pimentel D.R., Wang B., Connors L.H., Skinner M. et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004; 94: 1008–10.
  7. Shi J., Guan J., Jiang B., Brenner D.A., Del Monte F., Ward J.E. et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl AcadSci USA. 2010; 107: 4188–93.
  8. Campioni S., Mannini B., Zampagni M., Pensalfini A., Parrini C., Evangelisti E.et al. A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol. 2010; 6: 140–7.
  9. Peng S., Larsson A., Wassberg E., Gerwins P., Thelin S., Fu X., Westermark P. Role of aggregated medin in the pathogenesis of thoracic aortic aneurysm and dissection. Lab Invest. 2007; 87: 1195–205.
  10. Storozhakov G.I. Heart damage in amyloidosis. Zhurnal Serdechnaya nedostatochnost'. 2008; 9(5): 250-6. (in Russian)
  11. Zdanova E.A., Rameev V.V., Moiseev S.V., Kozlovskaya L.V., Safarova A.F. Amyloidosis of the heart: clinic, treatment, prognosis. Farmateka.2012; 9: 10-6. (in Russian)
  12. Dubrey S.W., Comenzo R.L. Amyloid diseases of the heart: current and future therapies. QJM. 2012; 105(7): 617-31.
  13. Ternacle J., Bodez D., Guellich A., Audureau E., Rappeneau S., Lim P.et al. Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. JACC Cardiovasc Imaging. 2016; 9: 126–38.
  14. Nucifora G., Muser D., Morocutti G., Piccoli G., Zanuttini D., Gianfagna P., Proclemer A. Disease-specific differences of left ventricular rotational mechanics between cardiac amyloidosis and hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2014; 307 (5): H680–8.
  15. Nemes A., Foldeak D., Domsik P., Kalapos A., Sepp R., Borbényi Z., Forster T. Different patterns of left ventricular rotational mechanics in cardiac amyloidosis – results from the three-dimensional speckle-tracking echocardiographic MAGYAR-Path Study. Quant Imaging Med Surg. 2015; 5 (6): 853–7.
  16. Pavlyukova E.M., Kuzhel D.A., Matyushin G.V., Savchenko E.A., Filippova S.A. Left ventricular rotation, twist and untwist: physiological role and clinical relevance. Ratsional'naya farmakoterapiya v kardiologii. 2015; 11 (1): 68–78. (in Russian)
  17. Falk R., Alexander K., Liao R., Dorbala S. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Col lCardiol 2016; 68(12): 1323–41.
  18. Dvoretsky L.I., Karpova O.Y., Alexandrova E.N., Petrova S.Y. Amyloidosis heart in elderly. Arhiv vnutrenney meditsiny.2015; (6):28-36. (in Russian)
  19. Gonzalez-Lуpez E., Gallego-Delgado M., Guzzo-Merello G., de Haro-Del Moral F.J., Cobo-Marcos M., Robles C. et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur. Heart J. 2015; 36: 2585–94.
  20. Steiner I., Hajkova P. Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. Cardiovasc Pathol. 2006; 15: 287–90.
  21. Pinney J.H., Whelan C.J., Petrie A., Dungu J., Banypersad S.M., Sattianayagam P. et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013; 2: e000098
  22. Ueda M., Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegen. 2014; 3: 19.
  23. Rowczenio D.M., Noor I., Gillmore J.D., Lachmann H.J., Whelan C., Hawkins P.N. et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014; 35: E2403–12.
  24. Goffin Y. Microscopic amyloid deposits in the heart valves: a common local complication of chronic damage and scarring. J Clin Pathol. 1980; 33: 262–8.
  25. Röcken C., Peters B., Juenemann G., Saeger W., Klein H.U., Huth C., Roessner A., Goette A. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation. 2002; 106: 2091–97.
  26. Leone O., Boriani G., Chiappini B., Pacini D., Cenacchi G., Suarez M. et al. Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur. Heart J. 2004; 25: 1237–41.
  27. Mucchiano G., Cornwell 3rd G.G., Westermark P. Senile aortic amyloid: evidence for two distinct forms of localized deposits. Am J Pathol. 1992; 140: 871–7.
  28. Peng S., Westermark G.T., Näslund J., Häggqvist B., Glennert J., Westermark P. Medin and medin-amyloid in ageing inflamed and non-inflamed temporal arteries. J Pathol.2002; 196: 91–6.
  29. Enqvist S., Peng S., Persson A., Westermark P. Senile amyloidoses--diseases of increasing importance. Acta Histochem. 2003; 105(4): 377-8.
  30. Larsson A., Malmström S., Westermark P. Signs of cross-seeding: aortic medin amyloid as a trigger for protein AA deposition. Amyloid. 2011; 18(4): 229-34.
  31. Mucchiano G.I., Haggqvist B., Sletten K., Westermark P. Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J Pathol. 2001; 193: 270–5.
  32. Kyle R.A., Linos A., Beard C.M., Linke R.P., Gertz M.A., O'Fallon W.M. et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.Blood 1992; 79: 1817–22.
  33. Palladini G., Comenzo R.L. The challenge of systemic immunoglobulin light-chain amyloidosis (Al). Subcell Biochem 2012; 65: 609–42.
  34. Desport E., Bridoux F., Sirac С., Delbes S., Bender S., Fernandez B. et al. AL-amyloidosis.Nefrologiya.2014; 18(4) : 36-50. (in Russian)
  35. Gertz M.A. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer Journal.2018; 8: 44-56.
  36. Rameeva A.S., Rameev V.V., Moiseev S.V., Tao P.P, Kozlovskaya L.V. Amyloid heart disease: pathomorphology, diagnostic approaches and treatment options. Consilium Medicum. 2018; 20 (12): 15–22. (in Russian)
  37. Rameev V.V., Kozlovskaya L.V. Amyloidosis: modern methods of diagnosis and treatment. Effektivnaya farmakoterapiya. Urologiya i nefrologiya. Spetsial'nyy vypusk: aktual'nye voprosy nefrologii. 2012; 6-15. (in Russian)
  38. Perfetti V., Casarini S., Palladini G., Vignarelli M.C., Klersy C., Diegoli M. et al. Analysis of V(lambda)- J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood. 2002; 100: 948-53.
  39. Madan S., Dispenzieri A., Lacy M.Q., Buadi F., Hayman S.R., Zeldenrust S.R.et al. Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma. Mayo Clin Proc. 2010;.85(3): 232- 38.
  40. Walther D.M., Kasturi P., Zheng M., Pinkert S., Vecchi G., Ciryam P. et al. Widespread proteome remodeling and aggregation in aging C. elegans. Cell 2015; 161: 919–32.
  41. Rameev V.V., Myasnikov R.P., Vinogradov P.P., Kozlovskaya L.V., Moiseev S.V., Fomicheva E.I. et al. Systemic ATTR-amyloidosis, a Rare Form of Internal Organ Damage. Ratsional'naya farmakoterapiya v kardiologii. 2019; 15(3): 349-58. (in Russian)
  42. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952; 75: 408-27.
  43. Connors L.H., Lim A., Prokaeva T., Roskens V.A., Costello C.E. Tabulation of human transthyretin (TTR) variants. Amyloid.2003; 10: 160-84.
  44. Sattianayagam P.T., Hahn A.F., Whelan C.J., Gibbs S.D., Pinney J.H., Stangou A.J. et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012; 33: 1120– 7.
  45. Connors L.H., Prokaeva T., Lim A., Théberge R., Falk R.H., Doros G. et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J. 2009; 158: 607-14.
  46. Falk R.H. Diagnosis and management of the cardiac amyloidosis. Circulation. 2005; 112: 2047–60.
  47. Benson M.D. Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid. 2005; 12: 75–87.
  48. Kebbel A., Rocken C. Immunohistochemical classification of amyloid in surgical pathology revisited. Am J Surg Pathol. 2006; 30: 673–83.
  49. von Hutten H., Mihatsch M., Lobeck H., Rudolph B., Eriksson M., Rocken C. Prevalence and origin of amyloid in kidney biopsies. Am J Surg Pathol. 2009; 33: 1198–205.
  50. Kieninger B., Eriksson M., Kandolf R., Schonland P., Kristen A., Hegenbart U. et al. Amyloid in endomyocardial biopsies. Virchows Arch. 2010; 456: 523–32.
  51. Freudenthaler S., Hegenbart U., Schonland S., Behrens H., Kruger S., Rocken C. Amyloid in biopsies of the gastrointestinal tract — a retrospective observational study on 542 patients. Virchows Arch. 2016; 468: 569–77.
  52. Garcia Y., Collins A.B., Stone J.R. Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis. Human Pathol.2018; 72: 71–9.
  53. Morris A.D., Smith R.N., Stone J.R. The pathology and changing epidemiology of dialysis-related cardiac beta-2 microglobulin amyloidosis. Cardiovasc Pathol. 2019; 42: 30-5. doi: 10.1016/j.carpath.2019.05.002
  54. Masuda M., Ishimura E., Ochi A., Tsujimoto Y., Tahara H., Okuno S. et al. Serum β2- microglobulin correlates positively with left ventricular hypertrophy in long-term hemodialysis patients. Nephron Clin Pract. 2014; 128: 101–6.
  55. Booth D.R., Booth S.E., Gillmore J.D., Hawkins P.N., Pepys M.B. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid. 1998; 5: 262-5.
  56. Papa R., Lachmann HJ. Secondary, AA, Amyloidosis. Rheum Dis Clin North Am. 2018; 44 (4): 585-603.
  57. Brunger A.F., Nienhuis H.L.A., Bijzet J., Hazenberg B.P.C. Causes of AA amyloidosis: a systematic review. Amyloid. 2020; 27(1):1-12.
  58. Alkhawam H., Patel D., Nguyen J., Easaw S.M., Al-Sadawi M., Syed U.et al. Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options. Acta Cardiol. 2017; 72(4): 380-9.
  59. Lane T., Loeffler J.M., Rowczenio D.M., Gilbertson J.A., Bybee A., Russell T.L. et al. AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum. 2013; 65: 1116–21.
  60. Larsen C.P., Kossmann R.J., Beggs M.L., Solomon A., Walker P.D. Clinical, morphologic, and genetic features of renal leukocyte chemotactic factor 2 amyloidosis. Kidney International. 2014; 86: 378-82.
  61. Said S.M., Sethi S. Valeri A.M., Chang A., Nast C.C., Krahl L. et al. Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int. 2014; 86: 370–7.
  62. Kyle R.A., Bayrd E.D. Amyloidosis: Review of 236 cases. Medicine (Baltimore). 1975; 54: 271-99.
  63. Wyse D.G., Waldo A.L., DiMarco J.P., Domanski M.J., Rosenberg Y., Schron E.B.et al. A comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. N. Engl. J. Med. 2002; 347: 1825–33.
  64. Nademanee K. et al. Benefits and risks of catheter ablation in elderly patients with atrial fibrillation. Heart Rhythm.2015; 12: 44–51.
  65. Agnihotri K., Patel P., Sharma K., Bhatia S., Shantha G., Patel N. et al. Abstract 18919: Outcomes of Catheter Ablation for Atrial Fibrillation in the Elderly-Data From the Largest Inpatient Registry (2011–2014). Circulation.2017; 136: A18919–A18919.
  66. Krishnappa D., Dykoski R, Can I., Mbai M., Anand I.S., Viorel Florea V. et al. Atrial Fibrillation in the Elderly: The Role of Sub-Clinical Isolated Cardiac Amyloidosis. Scientific Reports.2019; 9:16584.
  67. Treibel T.A., Fontana M., Gilbertson J.A., Castelletti S., White S.K., Scully P.R. et al. Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. Circ Cardiovasc Imaging. 2016; 9: e005066.
  68. Kristen A.V., Dengler T.J., Hegenbart U., Schonland S.O., Goldschmidt H., Sack F.U. et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm.2008; 5(2): 235—40.
  69. Vaxman I., Gertz M. Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis. Acta Haematol. 2019;141:93–106.
  70. Nonka T.G., Repin A.N. Cardiac amyloidosis. Diagnostics and treatment of amyloid cardiomyopaphy.Case report. Klinicheskaya Meditsina. 2015; 93(4): 66-73. (in Russian).
  71. Martinez-Naharro A., Hawkins P.N., Fontana M. Cardiac amyloidosis. Clinical Medicine. 2018; 18 (2): 30-5.
  72. Palladini G., Barassi A., Klersy C., Pacciolla R., Milani P., Sarais G. et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010; 116: 3426–30.
  73. Sachchithanantham S., Berlanga O., Alvi A., Mahmood S.A., Lachmann H.J., Gillmore J.D. et al. Immunoparesis defined by heavy+light chain suppression is a novel marker of longterm outcomes in cardiac AL amyloidosis. Br J Haematol. 2017; 179 (4): 575–85.
  74. Muchtar E., Dispenzieri A., Kumar S.K., Buadi F.K., Lacy M.Q., Zeldenrust S. et al. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Leukemia.2017; 31(1): 92–9.
  75. Obici L., Perfetti V., Palladini G., Moratti R., Merlini G.Clinical aspects of systemic amyloid diseases. Biochimica et Biophysica Acta. 2005; 1753: 11–22.
  76. Harrison J.S., Frazier S.R., McConnell D.D. Yasar S.J., Melnyk N., Salaru G. Evidence of both von Willebrand factor deposition and factor V deposition onto AL amyloid as the etiology of a severe bleeding diathesis. Blood Coagulation & Fibrinolysis. 2017; 28: 342-47.
  77. Gertz M.A., Kyle R.A. Myopathy in primary systemic amyloidosis. Journal of Neurology, Neurosurgery, and Psychiatry.1996; 60: 655-60.
  78. Yen T., Chen F.W., Witteles R.M., Liedtke M., Nguyen L.A. Clinical implications of gastrointestinal symptoms in systemic amyloidosis. Neurogastroenterology and Motility. 2018; 30: e3229.
  79. Ozdemir D., Dagdelen S., Erbas T. Endocrine involvement in systemic amyloidosis. Endocrine Practice. 2010; 16: 1056-1063.
  80. Mahmood S., Bridoux F., Venner C.P., Sachchithanantham S., Gilbertson J.A., Rowczenio D. et al. Natural history and outcomes in localized immunoglobulin light-chain amyloidosis: a long-term observational study. Lancet Haematol.2015; 2(6): e241–50.
  81. Westermark P., Bergström J., Solomon A., Murphy C., Sletten K. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural consideration. Amyloid. 2003; 10 Suppl 1: 48–54.
  82. Ueda M., Ando Y., Haraoka K., Katsuragi S., Terasaki Y., Sugimoto M., Sun X., Uchino M. Aging and transthyretin-related amyloidosis: pathologic examinations in pulmonary amyloidosis. Amyloid. 2006; 13: 24–30.
  83. Ruberg F.L., Berk J.L. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012; 126: 1286-300.
  84. Koike H., Tanaka F., Hashimoto R. Tomita M., Kawagashira Y., Iijima M.et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: Analysis of late onsetcases from non-endemic areas. Journal of Neurology, Neurosurgery, and Psychiatry. 2012; 83: 152-8.
  85. Jin K., Sato S., Takahashi T., Nakazaki H., Date Y., Nakazato M.et al. Familial leptomeningeal amyloidosis with a transthyretin variant Asp18Gly representing repeated subarachnoid haemorrhages with superficial siderosis. Journal of Neurology, Neurosurgery & Psychiatry. 2004; 75: 1463-6.
  86. Beckius S., Shah K. Intracranial and systemic manifestations of familial leptomeningeal amyloidosis, as seen on CT and MRI. Radiol Case Rep. 2018; 13(6): 1179-84.
  87. Lousada I., Comenzo R.L., Landau H., Guthrie S., Merlini G. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther. 2015; 32: 920–8.
  88. Kourelis T.V., Kumar S.K., Go R.S., Kapoor P., Kyle R.A., Buadi F.K. et al. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Am J Hematol. 2014; 89: 1051–4.
  89. Merlini G., Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program. 2012; 2012: 595-603.
  90. Palladini G., Campana C., Klersy C., Balduini A., Vadacca G., Perfetti V. et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003; 107: 2440-5.
  91. Dispenzieri A., Gertz M.A., Kumar S.K., Lacy M.Q., Kyle R.A., Saenger A.K. et al. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart. 2014; 100: 383-8.
  92. Kumar S., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., Colby C. et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J ClinOncol. 2012; 30: 989-95.
  93. Palladini G., Foli A., Milani P., Russo P., Albertini R., Lavatelli F. et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol.2012; 87: 465-71.
  94. Oerlemans M. I. F. J. , Rutten K. H. G., Minnema M. C., Raymakers R. A. P., Asselbergs F. W., de Jonge N. Cardiac amyloidosis: the need for early diagnosis. Neth Heart J. 2019; 27: 525-36.
  95. Murtagh B., Hammill S.C., Gertz M.A., Kyle R.A., Tajik A.J., Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol.2005; 95(4): 535-7.
  96. Bellavia D., Pellikka P.A., Dispenzieri A., Scott C.G., Al-Zahrani G.B., Grogan M. et al. Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study. Eur Heart J Cardiovasc Imaging.2012; 13(8): 680-9.
  97. Lee M.H., Lee S.P., Kim Y.J., Sohn D.W. Incidence, diagnosis and prognosis of cardiac amyloidosis. Korean Circ J. 2013; 43(11): 752-60.
  98. Koyama J., Ray-Sequin P.A., Falk R.H. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003; 107: 2446–52.
  99. Bellavia D., Pellikka P.A., Abraham T.P., Al-Zahrani G.B., Dispenzieri A., Oh J.K. et al. Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two dimensional and Doppler echocardiography. Am J Cardiol. 2008; 101: 1039–45.
  100. Santarone M., Corrado G., Tagliagambe L.M., Manzillo G.F., Tadeo G., Spata M., Longhi M. Atrial thrombosis in cardiac amyloidosis: diagnostic contribution of transesophageal echocardiography. J Am Soc Echocardiogr. 1999; 12: 533–6.
  101. Dubrey S.W., Cha K., Anderson J., Chamarthi B., Reisinger .J, Skinner M. et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM.1998; 91(2): 141–57.
  102. Gertz M.A., Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid.2010; 17 (Suppl. 1): 48–9.
  103. Phelan D., Collier P., Thavendiranathan P., Popović Z.B., Hanna M., Plana J.C. et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012; 98: 1442–8.
  104. Pandey T., Alapati S., Wadhwa V., Edupuganti M.M., Gurram P., Lensing S., Jambhekar K.Evaluation of myocardial strain in patients with amyloidosis using cardiac magnetic resonance feature tracking. Curr Probl Diagn Radiol.2017; 46: 288–94.
  105. Falk R., Quarta C., Dorbala S. How to Image Cardiac Amyloidosis: A Focused Practical Review. Circ Cardiovasc Imaging.2014; 7(3): 552-62.
  106. Phelan D., Thavendiranathan P., Popovic Z. Collier P., Griffin B., Thomas J.D., Marwick T.H. Application of a parametric display of two dimensional speckle-tracking longitudinal strain to improve the etiologic diagnosis of mild to moderate left ventricular hypertrophy. J Am Soc Echocardiog 2014; 27: 888–95.
  107. Pagourelias E.D., Mirea O., Duchenne J., Van Cleemput J., Delforge M., Bogaert J., Kuznetsova T., Voigt J.U. Echo parameters for differential diagnosis in cardiac amyloidosis: a head‐to‐head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging. 2017; 10: e005588.
  108. Tang C.X., Petersen S.E., Sanghvi M.M., Lu G.M., Zhang L.J. Cardiovascular magnetic resonance imaging for amyloidosis: The state-of-the-art. Trends Cardiovasc Med. 2019; 29(2):83-94.
  109. Sinitsyn V.E., Mershina E.A., Larina O.M. The possibilities of magnetic resonance imaging in the diagnosis of cardiomyopathy. Klinicheskaya i eksperimental'naya hirurgiya. Zhurnal imeni akademika B.V. Petrovskogo. 2014; 1: 54–63. (in Russian)
  110. Patel K.S., Hawkins PN. Cardiac amyloidosis: where are we today? J Intern Med. 2015; 278 (2): 126–44.
  111. Bhatti S., Watts .E, Syed F., Vallurupalli S., Pandey T., Jambekar K. et al. Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2016; 17(9): 970–7.
  112. Roller F.C., Harth S, Schneider C., Krombach G.A.T1, T2 Mapping and Extracellular Volume Fraction (ECV): Application, Value and Further Perspectives in Myocardial Inflammation and Cardiomyopathies. RoFo. 2015; 187: 760–70.
  113. Ridouani F., Damy T., Tacher V., Derbel H., Legou F., Sifaoui I.et al. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J Cardiovasc Magn Reson. 2018; 20(1): 58. doi: 10.1186/s12968-018-0478-3.
  114. Yamamoto H., Yokochi T.Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail.2019; 6(6): 1128–39.
  115. Chang I.C.Y., Arani A., Poigai A.S., Grogan M., Dispenzieri A., Araoz P.A. Feasibility study of cardiac magnetic resonance elastography in cardiac amyloidosis. Amyloid.2017; 24(sup1): 161.
  116. Can Yang J.C., Fox J., Chen C., Yu A.F. Cardiac ATTR amyloid nuclear imaging—not all bone scintigraphy radionuclide tracers are created equal.J Nucl Cardiol. 2018; 25 (5): 1879–84.
  117. Picken M.M. Amyloidosis-where are we now and where are we heading? Arch Pathol Lab Med. 2010; 134: 545-51.
  118. Gillmore J.D., Maurer M.S., Falk R.H., Merlini G., Damy T., Dispenzieri A. et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016; 133: 2404–12.
  119. Dorbala S., Cuddy S., Falk R.H. How to Image Cardiac Amyloidosis: A Practical Approach. JACC Cardiovasc Imaging. 2019 Oct 11. pii: S1936-878X(19) 30713-2. doi: 10.1016/j.jcmg.2019.07.015
  120. Castano A., Grogan M., Johnson G.B., Dispenzieri A., Ruberg F.L., Berk J.L. et al. Multicenter experience of technetium pyrophosphate scanning for diagnosing TTR cardiac amyloid: a revival in nuclear cardiology. J Card Failure. 2015; 21 (8): S85.
  121. Hutt D.F., Quigley A.M., Page J., Hall M.L., Burniston M., Gopaul D. et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging.2014; 15: 1289–98.
  122. Ramsay S.C., Cuscaden C. The current status of quantitative SPECT/CT in the assessment of transthyretin cardiac amyloidosis. J Nucl Cardiol.2019 Nov 5. doi: 10.1007/s12350-019-01935-1.
  123. Trivieri M.G., Dweck M.R., Abgral R., Robson P.M., Karakatsanis N.A., Lala A. et al.18F-Sodium Fluoride PET/MR for the Assessment of Cardiac Amyloidosis. J Am Coll Cardiol. 2016; 68(24): 2712-4.
  124. Duston M.A., Skinner M., Shirahama T., Cohen A.S. Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years’ experience. Am J Med. 1987; 82(3): 412–4.
  125. Petruzziello F., Zeppa P., Catalano L., Cozzolino I., Gargiulo G., Musto P. et al. Amyloid in bone marrow smears of patients affected by multiple myeloma. Ann Hematol.2010 May; 89(5): 469–74.
  126. Foli A., Palladini G., Caporali R., Verga L., Morbini P., Obici L. et al. The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid. 2011; 8(Suppl. 1):80–2.
  127. Bochtler T., Hegenbart U., Kunz C., Benner A., Seckinger A., Dietrich S. et al. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid. 2014; 21: 9–17.
  128. Bochtler T., Hegenbart U., Kunz C., Granzow M., Benner A., Seckinger A. et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015; 33: 1371–8.
  129. Vrana J.A., Gamez J.D., Madden B.J., Theis J.D., Bergen H.R. 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009; 114(24): 4957–9.
  130. Fernandez de Larrea C., Verga L., Morbini P., Klersy C., Lavatelli F., Foli A. et al. A practical approach to the diagnosis of systemic amyloidoses. Blood. 2015; 125(14): 2239–44.
  131. Ukholkina G.B., Kuchin G.A., Bychkova O.P., Chikhirev O.A. Cardiac amyloidosis in clinical practice. Serdechnaya nedostatochnost'. 2016; 1: 57-68. (in Russian)
  132. Rajkumar S.V., Dimopoulos M.A., Palumbo A., Blade J., Merlini G., Mateos M.V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538–48.
  133. Palladini G., Russo P., Bosoni T., Verga L., Sarais G., Lavatelli F. et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009; 55: 499-504.
  134. Grogan M., Scott C.G., Kyle R.A., Zeldenrust S.R., Gertz M.A., Lin G. et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016; 68: 1014-0.
  135. Phull P., Sanchorawala V., Connors L.H., Doros G., Ruberg F.L., Berk J.L. et al. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid. 2018: 1-6.
  136. Comenzo R.L., Zhou P., Fleisher M., Clark B., Teruya-Feldstein J. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood. 2006; 107(9): 3489-91.
  137. Shimazaki C., Hata H., Iida S., Ueda M., Katoh N., Sekijima Y. et al. Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan. Intern Med. 2018; 57(2): 181-7.
  138. Pereira N.L., Grogan M., Dec G.W. Spectrum of Restrictive and Infiltrative Cardiomyopathies. Part 1 of a 2-Part Series. Journal of the American College of Cardiology. 2018; 71(10).
  139. Nuvolone M., Milani P., Palladini G., Merlini G. Management of the elderly patient with AL amyloidosis. European Journal of Internal Medicine. 2018; 58: 48-56.
  140. Quock T.P., Yan T., Chang E., Guthrie S., Broder M.S. Epidemiology of AL amyloidosis: a realworld study using US claims data. Blood Adv. 2018; 2(10): 1046-53.
  141. Rubinow A., Skinner M., Cohen A.S. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981; 63: 1285-8.
  142. Lin G., Dispenzieri A., Kyle R, Grogan M., Brady P.A. Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol. 2013; 24(7): 793-8.
  143. Siddiqi O.K., Ruberg F.L. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018; 28(1): 10-21.
  144. Sayed R.H., Rogers D., Khan F., Wechalekar A.D., Lachmann H.J, Fontana M. et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J. 2015; 36(18): 1098–105.
  145. Bellavia D., Pellikka P.A., Abraham T.P., Al-Zahrani G.B., Dispenzieri A., Oh J.K. et al. Hypersynchronisation by tissue velocity imaging in patients with cardiac amyloidosis. Heart. 2009; 95: 234-0.
  146. Caccialanza R., Palladini G., Cereda E., Bonardi C., Milani P., Cameletti B. et al. Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis. Nutrition.2015; 31: 1228–34.
  147. Muchtar E., Gertz M.A., Kumar S.K., Lacy M.Q., Dingli D., Buadi F.K. et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017; 129: 2111–9.
  148. Wechalekar A.D., Gillmore J.D., Bird J., Cavenagh J., Hawkins S., Kazmi M. et al. BCSH Committee. Guidelines on the management of AL amyloidosis. Br J Haematol. 2015; 168(2): 186–206.
  149. D’Souza A., Dispenzieri A., Wirk B., Zhang M.J., Huang J., Gertz M.A. et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Journal of Clinical Oncology. 2015; 33: 3741-49.
  150. Milani P., Merlini G., Palladini G. Novel Therapies in Light Chain Amyloidosis. Kidney Int Rep. 2018; 3: 530-41.
  151. Gertz M.A., Lacy M.Q., Dispenzieri A. Gastineau D.A., Chen M.G., Ansell S.M. et al.Stem cell transplantation for the management of primary systemic amyloidosis. Am. J. Med. 2002; 113: 549-55.
  152. Comenzo R.L., Gertz M.A.Autologous stem cell transplantation for primary systemic amyloidosis. Blood.2002; 99: 4276-82.
  153. Sanchorawala V, Sun F, Quillen K, Sloan J.M., Berk J.L., Seldin D.C.Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood. 2015;126: 2345-47.
  154. Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016; 128: 159–68.
  155. Alexander K.M., Singh A., Falk R.H.Novel pharmacotherapies for cardiac amyloidosis. Pharmacol Ther. 2017; 180: 129-38.
  156. Palladini G., Milani P., Foli A., Obici L., Lavatelli F., Nuvolone M. et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a riskadapted approach. Haematologica. 2014; 99: 743-50.
  157. Kastritis E., Leleu X., Arnulf B., Zamagni E., Cibeira M.T., Kwok F. et al. A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis. Blood. 2016; 128: 646.
  158. Venner C.P., Gillmore J.D., Sachchithanantham S., Mahmood S., Lane T., Foard D. et al. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia. 2014; 28: 2304-10.
  159. Palladini G., Sachchithanantham S., Milani P. Gillmore J., Foli A., Lachmann H.et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015; 126:.612-5.
  160. Palladini G., Milani P., Foli A., Basset M., Russo F., Perlini S. et al. Presentation and outcome with second line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood.2017; 131: 525-32.
  161. Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017; 130(7): 900–2.
  162. Leung N., Thome S.D., Dispenzieri A. Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone. Haematologica. 2018; 103(3):e135-7.
  163. Renz M., Torres R., Dolan P.J., Tam S.J., Tapia J.R., Li L.et al. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis (y). Amyloid. 2016; 23: 168-77.
  164. Edwards C.V., Gould J., Langer A.L., Mapara M., Radhakrishnan J., Maurer M.S. et al. Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11–1F4 in patients with AL amyloidosis. Amyloid.2017; 24: 58–9.
  165. Lacy M.Q., Dispenzieri A., Hayman S.R., Kumar S., Kyle R.A., Rajkumar S.V. et al. Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. JHeart Lung Transplant.2008; 27(8): 823–9.
  166. Sekijima Y. Transthyretin (ATTR) amyloidosis: Clinical spectrum, molecular pathogenesis and disease modifying treatments. Journal of Neurology, Neurosurgery, and Psychiatry. 2015; 86: 1036-43.
  167. Rameev V.V. Modern methods of diagnosis and treatment of transthyretin hereditary amyloidosis. Managepain. 2018; 1: 20–4. (in Russian)
  168. Maurer M.S., Schwartz J.H., Gundapaneni B., Elliott P.M., Merlini G., Waddington-Cruz M. et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. The New England Journal of Medicine. 2018; 379: 1007-16.
  169. Adams D., Suhr O.B., Hund E., Obici L., Tournev I., Campistol J.M. et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016; 29 (Suppl. 1): S14-S26.
  170. Berk J.L., Suhr O.B., Obici L., Sekijima Y., Zeldenrust S.R., Yamashita T. et al. Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial. JAMA. 2013; 310: 2658-67.
  171. Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther. 2014; 39 (3): 225-33.
  172. Adams D., Gonzalez-Duarte A., O’Riordan W.D., Yang C.C., Ueda M., Kristen A.V. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine. 2018; 379: 11-21.
  173. Ugurlu S., Hacioglu A., Adibnia Y., Hamuryudan V., Ozdogan H. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever. Orphanet Journal of Rare Diseases.2017; 12: 105.
  174. Pepys M.B., Herbert J., Hutchinson W.L., Tennent G.A., Lachmann H.J., Gallimore J.R. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 2002; 417: 254-59.
  175. Richards D.B., Cookson L.M., Barton S.V., Liefaard L., Lane T., Hutt D.F. et al. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Science Translational Medicine.2018; 10: 3128.

Supplementary files

Supplementary Files
Action
1. Fig. 1. Pseudo-infarction ECG changes in a 71-year-old patient with AKMP.

Download (74KB)
2. Figure 2. Echocardiogram of a patient with AL-amyloidosis, severe pseudohypertrophy of the left ventricle.

Download (441KB)
3. Fig. 3. Electrocardiogram of a patient of 80 years with AKMP. QRS low voltage in limb leads and chest leads, LV wall thickness - 1.6 cm.

Download (49KB)
4. Fig. 4. Deposits of amyloid in the atrium. Stained with hematoxylin and eosin (A) and Congo red in a bright field (B). SW × 20.

Download (397KB)
5. Fig. 5. Deposits of amyloid in the atrium. Congo red stain, polarization microscopy. SW × 20.

Download (28KB)
6. Fig. 6. Deposits of amyloid in the myocardium of the left ventricle. Stained with hematoxylin and eosin (A), Congo red - light (B) and polarization (C) microscopy. SW × 20.

Download (608KB)
7. Fig. 7. Deposits of amyloid in the thyroid gland. Congo red stain - light (A) and polarization (B) microscopy. SW × 20.

Download (316KB)

Copyright (c) 2020 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 01016 от 19.07.1995 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80632 от 15.03.2021 г
.



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies